Development of multtarget agents possessing soluble epoxide hydrolase inhibitory activity

Kerstin Hiesingerb, Karen M. Wagnerb, Bruce D. Hammockb, Ewgenij Proschaka, Sung Hee Hwangb,⁎

a Institute of Pharmaceutical Chemistry, Goethe University of Frankfurt, Max-von-Laue Str. 9, D-60439, Frankfurt am Main, Germany
b Department of Entomology and Nematology and UC Davis Comprehensive Cancer Center, University of California, Davis, One Shields Avenue, Davis, CA 95616, USA

ARTICLE INFO

Keywords:
Polypharmacology
Multitarget agents
Dual inhibitors/modulators
Soluble epoxide hydrolase

ABSTRACT

Over the last two decades polypharmacology has emerged as a new paradigm in drug discovery, even though developing drugs with high potency and selectivity toward a single biological target is still a major strategy. Often, targeting only a single enzyme or receptor shows lack of efficacy. High levels of inhibitor of a single target also can lead to adverse side effects. A second target may offer additive or synergistic effects to affecting the first target thereby reducing on- and off-target side effects. Therefore, drugs that inhibit multiple targets may offer a great potential for increased efficacy and reduced the adverse effects. In this review we summarize recent findings of rationally designed multitarget compounds that are aimed to improve efficacy and safety profiles compared to those that target a single enzyme or receptor. We focus on dual inhibitors/modulators that target the soluble epoxide hydrolase (sEH) as a common part of their design to take advantage of the beneficial effects of sEH inhibition.

1. Introduction

Drug discovery has been dominated by the approach of using a single protein target to treat a single disease with a single chemical entity. Such drugs possess high selectivity and potency against their specific targets and there is no doubt that this approach will continue to be a major strategy of drug development. Despite this, there are pitfalls of the single-target approach and a continued need for improvement to increase efficacy and/or reduce on- and off-target adverse events. Multitarget drugs [1] (also known as designed multiple ligands (DMLs) [2] or hybrid molecules [3]) emerged as a strategy to overcome these problems. Studies on FDA-approved new molecular entities from 2000 to 2015 [4] and from 2015 to 2017 [1] support the idea that polypharmacology is particularly useful for treating complex diseases such as inflammation, cancers and metabolic syndrome [5,6]. Overall drug discovery based on small molecules is decreasing due in part to the rise and success of biologics such as immunotherapy for cancers [7]. However, the number of FDA-approved drugs that interact with multitargets is growing. One reason for this growth is the approval of pankinase inhibitors to treat some cancers which are refractory to
monotherapy due to the nature of the disease. Multitarget drugs aim to improve efficacy by addressing more targets involved in the disease. The additive or synergistic effects of multitarget drugs also permit a reduced effective dose, which in turn, minimizes off-target effects. Some single-target drugs may have off-target side-effects or on-target side effects (mechanism-based toxicity) that limit their effective doses. These can potentially be alleviated with the help of including a secondary target that attenuates the side effect. The soluble epoxide hydrolase (sEH) is an enzyme in the arachidonic acid (ARA) cascade which participates in the degradation of epoxide metabolites formed from cytochrome P450 (CYP450) action on ARA and other unsaturated fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [8]. Inhibiting sEH and thus sustaining the titers of endogenous epoxy fatty acid (EpFAs) metabolites has been shown to be beneficial in various disease pathologies. Therefore, in this review, we focus on recent findings of dual inhibitors/modulators that are rationally designed to concurrently inhibit sEH as one of their multiple targets and the role of these compounds in various diseases.

2. Development and application of dual inhibitors of using sEH as a target

The soluble epoxide hydrolase (EC 3.3.2.10, sEH) is an alpha/beta-hydrolase fold enzyme which metabolizes various EpFAs into their corresponding diols [9]. The enzyme exists in mammals as a domain-swapped homodimer and is highly conserved among species [10]. sEH is well-expressed throughout the mammalian body with the highest levels found in the liver and kidney. The C-terminal domain of the enzyme houses the catalytic site for epoxide hydrolysis of EpFAs and the N-terminal has phosphatase activity with an uncertain biological role. Pharmacological inhibition of sEH has been used as a strategy with great success to investigate the biological role of the EpFAs in vivo.

2.1. Dual inhibition of sEH and enzymes within the ARA cascade

2.1.1. ARA metabolism and biological pathways

Several biological processes such as inflammation and allergies are mediated by ARA metabolites, named eicosanoids. The cascade starts with the release of ARA from cellular membranes by phospholipases, commonly type-IV cytosolic PLA2 α (cPLA2α) [11] and others such as diacylglycerol lipase. ARA is then transformed into eicosanoids by three main metabolic pathways; the cyclooxygenase (COX) pathway produces prostanoids, the lipoxigenases (LOXs) catalyze the formation of lipoxins (LXs), leukotrienes (LTs) and hydroxyeicosatetraenoic acids (HETEs), and the CYP450 pathway forms epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE) (Fig. 1). Although here the focus is on ARA, it is important to note that EPA and other unsaturated fatty acids are also metabolized by the same enzymes of this cascade and the EpFAs of all these lipid classes are also substrates of sEH [8]. Esters and amides of fatty acids and increasingly their oxidized metabolites described above could be considered another branch of the ARA cascade, but they usually are classified as endocannabinoids.

2.1.1.1. The CYP450 pathway. The CYP450s are a large family of heme containing enzymes that are widely expressed in the body and across species [12]. They are primarily monoxygenases with some substrate selectivity. The reactions of these CYP450 enzymes are selective, but by no means specific. Also, these hydroxylation and epoxidation reactions are carried out by other CYP450 enzymes, often at high rate, and they can also be induced by xenobiotics [12]. CYP4A enzymes convert ARA into the vasoconstrictive 20-HETE [13], CYP2C and CYP2J2 are known to transform ARA into a variety of oxidized products but largely EETs in many tissues [12]. Four regioisomers of EETs, the 5,6-, 8,9-, 11,12-, and 14,15-EETs, are formed depending on where the substrate is oxidized [14]. EETs are autocrine and paracrine mediators in the renal and cardiovascular system and are vasodilatory and anti-inflammatory. They mediate hyperpolarization and vasorelaxation via activation of ion-channels and show mitogenic effects in the kidney [14]. They are sometimes considered as a single class of lipid leading to similar biological effect [15]. However, as studies become more sophisticated individual regioisomers appear to show different properties. Most of the described effects occur through activation of signal transduction pathways and modulation of gene expression [14]. Detailed biological effects mediated by EETs have been reviewed by Spector et al. [16], and distinct biological effects of individual regioisomers are currently under investigation.

2.1.1.2. The COX pathway. The COX enzymes exists as two isoforms, COX-1 and COX-2. COX-1 is constitutively expressed and produces prostanoids that function to maintain homeostasis and gastric epithelial cytoprotection [17]. In contrast, COX-2 is inducible by various stimuli such as inflammation, hormones and growth factors, and is therefore a more important source of prostanoid formation regarding inflammation and proliferative diseases such as cancers. However, COX-2 is also constitutively expressed in some tissues such as brain, kidney, and spinal cord [18]. COX isoforms exist as bifunctional homodimers and transform ARA into prostaglandin G _2 (PGG _2 ) via cyclooxygenase activity and then further into prostaglandin H _2 (PGH _2 ) via peroxidase activity. PGH _2 is further metabolized into several prostanoids by various isomerases and synthases in a cell specific manner [17]. Prostanoids induce several biological effects through binding to G-protein-coupled prostanoid receptors. In the gastroduodenal tract, prostaglandin E _2 (PGE _2 ), prostaglandin F _2α (PGF _2α ) and prostacyclin (PGI _2 ) maintain the normal mucosal integrity through mucus synthesis and secretion, hydrogen carbonate secretion, mucosal blood flow and cellular repair [19]. PGE _2 , PGD _2 , and thromboxane A _2 (TXA _2 ) play important roles in controlling vascular tone. TXA _2 causes platelet aggregation and vasoconstriction while PGI _2 mediates vasodilatation [20]. In inflammation, the common symptoms rubor (redness), calor (heat), tumor (swelling) and dolor (pain) are mediated by PGE _2 [17]. PGI _2 and PGE _2 also play important roles in pain sensation and hyperalgesia [21].

2.1.1.3. The LOX pathway. There are three major LOXs; 5-, 12- and 15-LOX named to reflect the major position of the oxygen atom inserted within the polyunsaturated fatty acids [22]. All LOX isoforms are dioxygenases and form hydroperoxides. 5-LOX inserts oxygen into ARA with the help of an iron atom in its catalytic site thereby generating 5-hydroperoxycicosatetraenoic acid (5-HpETE). Either the 5-HpETE is released and metabolized by glutathione peroxidase to the corresponding 5-HETE or further metabolized by 5-LOX. A dehydrogenation produces leukotriene A _4 (LTA _4 ) in a second enzymatic step. Ultimately, unstable LTA _4 is modified to generate leukotrienes and lipoxins. The LTA _4 hydrolase (LTA _4 H) transforms the LTA _4 into the proinflammatory leukotriene B _4 (LTB _4 ). The LTC _4 synthase (LTC _4 S) conjugates glutathione to LTA _4 . The generated leukotriene C _4 (LTC _4 ) can be modified into several other cysteinyl-
leukotrienes (LTD and LTE₄). 12- and 15-LOX are involved in the synthesis of lipoxins (e.g. LXA₄) which also play a role in the resolution inflammation [23]. Among the LOX enzymes, 5-LOX and the biosynthesis of the leukotrienes is the focus of this review. The 5-LOX accumulates either in the cytoplasm or in the nucleus until activation [24]. Two cofactors, Ca²⁺ and ATP, are needed for the activation of 5-LOX. Ca²⁺ influx recruits 5-LOX to the nuclear membrane and calcium binds allosterically to the 5-LOX promoting the attachment to the membrane. The ATP-activation mechanism is not fully understood; however, a common hypothesis is that it extends enzyme stability [25]. Furthermore, the 5-lipoxygenase activating protein (FLAP) is needed to recruit ARA from the membrane to the 5-LOX. Leukotrienes are paracrine lipid mediators that take part in chronic inflammatory diseases as well as in the innate immune system. For example, LTD₄ is an especially strong chemotactic substance for neutrophils, macrophages and eosinophils. LTD₄ induces several functions such as adhesion to vascular endothelial cells, release of lysosomal proteins, production of reactive oxygen species and transendothelial migration [26].

2.1.1.4. Crosstalk within the ARA cascade. Complex diseases, such as inflammation, need an intrinsic communication among the different metabolites derived from ARA. Therefore, it is not surprising that evidence is building for crosstalk among the pathways of this cascade [27]. One of the first examples of crosstalk is the observation of aspirin-induced asthma [28], also known as Samter’s syndrome or aspirin-exacerbated respiratory disease (AERD) [29]. In 1975 it was theorized that the asthma results from the inhibition of COX instead of an allergic reaction and Knapp et al. described that unmetabolized ARA is shunted into the 5-LOX pathway producing LTE₄ [30]. Paredes et al. [31] observed an increase of LTD₄ levels in human osteoarthritic subchondral osteoblast of osteoarthritis patients treated with a COX-2 selective inhibitor NS-398, suggesting the shunting of ARA substrate from the COX to the LOX pathway via over-expression of FLAP [32]. Jung et al. treated mice with progressive renal disease with the sEH and COX enzymes, also known as mPGES-1 and FLAP were inhibited, 5-HETE, LTs and PGE2 levels were reduced as expected, but this combination also led to shunting to other pathways.

2.1.2. Dual inhibitors of sEH and COX

Dual inhibitors of sEH and COX enzymes have been reviewed [35]. Therefore, we will focus on recent reports about this topic. Earlier COX inhibitors (known as non-steroidal anti-inflammatory drugs, NSAIDs) have been long known to be highly effective drugs for reducing both pain and inflammation. However, high doses of these commonly-used compounds were found to cause gastrointestinal erosion due to reduction of prostanoids that maintain mucosal integrity [38]. Thus, COX-2 selective inhibitors (coxibs) such as rofecoxib and celecoxib were developed with the aim of limiting gastrointestinal side effects of non-selective COX inhibition by NSAIDs, but they are known to cause cardiovascular problems and have black box warnings [39,40]. Although NSAIDs and coxibs continue to have a major beneficial effect in reducing suffering, it now appears that COX inhibitors in general have a variety of deleterious effects. In general, non-selective COX inhibitors have worse GI side effects than coxibs and coxibs worse cardiovascular effects than NSAIDs. This suggests that it may be impossible to avoid the mechanism-based adverse effects associated with COX inhibition simply by adjusting relative inhibition of COX-1 and COX-2, though COX inhibition is effective to attenuate the intended disease indications such as pain and inflammation. Simultaneous augmentation of CYP450-derived EETs along with COX inhibition exerts an additive response attenuating lipopolysaccharide (LPS)-induced pain and hypotension [41,42]. In addition, CYP450-derived EETs, especially 8,9-EETs, are further metabolized by COX enzymes to angiogenic 11-hydroxy-8,9-EETs [37,43]. Based on these findings, a single molecule that targets both sEH and COX-2, but not COX-1 has been developed, and it demonstrated analgesia in an animal model of pain [44]. The single molecule sEH/COX-2 dual inhibitor (4-(5-phenyl-3-{3-(4-trifluoromethyl-phenyl)-ureido}[propyl]-pyrazol-1-yl)-benzenesulfonamide, PTUPB, Fig. 2) was more efficacious than monotherapy (either a COX-2 selective inhibitor or an sEH inhibitor alone) and even surpassed the combination of both treatments in an LPS-induced inflammatory pain model.

In this example, beneficial effects of PTUPB have been shown in other pathological conditions such as kidney disease [45] and cancers [44-46]. PTUPB significantly suppressed tumor growth and metastasis in murine lung cancer model [46]. In this study there was no direct comparison between the dual sEH/COX-2 inhibitor and a combination of the treatments, however the multitargeted ligand approach was more effective than monotherapy. PTUPB also suppressed tumor growth of breast cancers [46] and glioblastoma [47]. As an adjuvant, it potentiated cisplatin and cisplatin/gemcitabine chemotherapy regimes in patient-derived xenograft (PDX) bladder cancer models [48]. In addition, PTUPB did not alter the ratio of PGI2 to TXA2 (an indication for a
potential cardiovascular complication associated with COX-2 inhibition) [40], suggesting that the additional sEH inhibition is beneficial [46]. In a carbon tetrachloride-induced mouse model of liver injury, co-administration of celecoxib and an sEH inhibitor or PTUPB decreased fibrotic markers, while celecoxib alone showed no beneficial effect [49]. Finally, pharmacological or genetic ablation of sEH has been shown to be a potential treatment of Parkinson’s disease models [50]. PTUPB also prevented the reduction of dopamine and its metabolites against rotenone-induced neurodegeneration in a Drosophila model of Parkinson’s disease [51].

2.1.3. Dual inhibitors of sEH and FLAP

One possible approach to influence the 5-LOX pathway is modulating the activity of the FLAP enzyme. Without FLAP the recruitment of ARA to 5-LOX is reduced and consequently the production of leukotrienes. Liu et al. observed an enhanced anti-inflammatory effect combining an sEH inhibitor with a FLAP inhibitor in a murine model [42]. This suggests that a dual inhibitor may have similar or even enhanced efficacy compared to co-administration. To investigate this possibility, a dual sEH/FLAP inhibitor would be necessary, and this strategy has been pursued. Temmel et al. identified the first dual inhibitor of FLAP and sEH in a pharmacophore-based virtual screening by developing ligand-based pharmacophore models for FLAP and using known models for sEH [52]. By screening a commercial virtual library, 20 hit compounds were identified. Among them, a compound (diflapolin) showed dual inhibition against FLAP (IC_{50} = 200 nM in cell-based assay) and sEH (IC_{50} = 20 nM in cell-free assay) but did not inhibit isolated 5-LOX in the cell-free assay (Fig. 3). Diflapolin blocked leukotriene formation and suppressed neutrophil infiltration in a zymosan-induced mouse peritonitis model [53]. Diflapolin also showed high selectivity and demonstrated no interaction with other enzymes that metabolize ARA such as COX1/2, 12/15-LOX, LTA4H, LTC4S, mPGES-1 and cPLA2. In addition, diflapolin did not show cytotoxicity and was equally effective as the FLAP inhibitor MK886.

2.1.4. Dual inhibitors of sEH and 5-LOX

The first dual inhibitors of sEH and 5-LOX were discovered by an in silico approach. Moser et al. identified 80 hits by screening virtual library of 37,429 compounds by applying pharmacophore models for both targets [54]. Among them, only one compound was identified as a 5-LOX/sEH dual inhibitor with moderate inhibitory activities (5-LOX IC_{50} = 36 μM, sEH IC_{50} = 3.5 μM, respectively) by in vitro cell-free assays (Fig. 4). Nandha et al. further optimized this initial hit compound by incorporating several known pharmacophores of both 5-LOX and sEH [55]. Based on this structure-activity relationship (SAR) study, several potent 5-LOX/sEH dual inhibitors ranging from low micromolar to high nanomolar potencies against both targets have been obtained. The anti-inflammatory effects of these compounds were investigated in a rat paw edema model. Several compounds of this series showed a significant inhibition of the edema, which is comparable to the reference compound, ibuprofen (Fig. 4).

Meier et al. developed a series of 5-LOX/sEH dual inhibitors by linking two pharmacophores [56]; an imidazo[1,2-a]pyridine motif from 5-LOX selective inhibitor EP6 [57] and a urea group from sEH selective inhibitors such as 12-(3-adamantan-1-yl-ureido) dodecanoic acid (AUDA) or 1-cyclohexyl-3-dodecyl urea (CDU) [58]. The SAR demonstrated that an n-propyl linker between two pharmacophores was required to maintain sEH inhibition, while not affecting 5-LOX inhibition (Fig. 5).

Achenbach et al. developed an in silico approach for fragment-based design of 5-LOX/sEH dual inhibitors [59]. The developed approach generated 274 hit fragments. Among them, 24 compounds were tested using STD-NMR and in vitro assays, finding five fragments that inhibited both targets. To demonstrate the feasibility of this approach, the authors screened their in-house library of compounds and found that a compound containing an aminothiazole core possessed better inhibitory activities against both targets (Fig. 6).

Meier et al. developed 5-LOX/sEH dual inhibitors by linking two pharmacophores; an N-hydroxy urea moiety from a 5-LOX inhibitor Zileuton and a urea group from an sEH inhibitor TPAA with an n-propyl linker [60]. The 4-trifluoromethoxyphenyl group which had been already used in earlier designs showed an excellent pharmacokinetic profile [61]. The 5-LOX/sEH dual inhibitor KM55 inhibited the
adhesion of leukocytes onto endothelial cells by impairing leukocyte function. The adhesive properties of KM55-treated THP-1 cells were reduced back to control levels, which was more effective compared to either Zileuton or TPAU (Fig. 7).

2.2. Dual inhibition of sEH and targets outside the ARA cascade

2.2.1. Dual inhibitors of sEH and PPAR

Several studies highlighted an extensive crosstalk between effects mediated by EETs and peroxisome proliferator-activated receptor (PPAR) signaling, which has been reviewed in detail by Spector and Norris [14]. PPARs belong to the family of nuclear receptors which are a group of three types of proteins (α, β/δ, γ) with differential tissue expression that act as transcription factors, regulate gene expression, and are activated by fatty acids and eicosanoids. Older PPARα agonists known collectively as fibrates, are potent hyperlipidemic agents. These were the first potent inducers found for the sEH [62]. Both PPARα and PPARγ agonists induce levels of sEH. Thus, the beneficial clinical effects of PPARα agonists are diminished, in part, by their induction of sEH. PPARs play multiple roles in lipid and glucose homeostasis, however, among these effects, the anti-inflammatory and oxidative stress-reducing properties of EETs which are associated with PPARγ activation, are of special importance [63,64]. Direct activation of PPARγ by synthetic agonists such as clinically approved thiazolidinediones (TZDs) leads to improved insulin sensitivity and lower blood glucose levels [65]. However, the major side effects of the TZD class are fluid retention and weight gain caused by PPARγ stimulation of epithelial sodium channel (ENaC)-mediated renal salt absorption [66], which limits the utility of these multimodal insulin sensitizers [67]. It was shown that sEH inhibition sustaining EETs levels led to reduced ENaC-mediated renal salt reabsorption [68–70]. Therefore, sEH inhibition might prevent the major undesired side effects of TZDs. Furthermore, TZDs are often associated with obesity-related hypertension, dyslipidemia, and heart disease within metabolic syndrome [71]. Similar to earlier observations in rodents [72], the adipose tissue of obese patients exhibits increased sEH levels [73], which leads to decreased PPAR transcriptional activity [74]. Thus, reinvestment of PPARα agonists, by inducing sEH, the TZDs antagonize some of their own clinically beneficial effects. These findings suggest that simultaneous inhibition of sEH and activation of PPARγ is a potential intervention for metabolic syndrome, leading to a concomitant improvement of blood pressure and blood glucose level. A study performed by Imig et al. tested this hypothesis with co-administration of the TZD rosiglitazone and the sEH inhibitor t-AUCB in spontaneously hypertensive obese rats [75]. The combined administration of both pharmacological agents led to synergistic improvement of vascular function and reduced fibrotic kidney damage. It should be noted that some early sEH inhibitors such as AUDA are not only EET mimics, but also PPARα agonists. The first dual PPARα/sEH modulators were developed by linking two known pharmacophores for both PPARα, γ, or δ, and sEH, and identified several moderate dual PPARγ/sEH and PPARα/sEH mediators [76]. The fusion of the N-Benzyl piperidine-4-carboxamide to diverse PPAR pharmacophores was less successful yielding dual PPARα/sEH modulators which exhibited low binding affinity combined with high molecular weight and lipophilicity [77]. Finally, the identification of N-benzyl benzamides as a merged PPAR/sEH pharmacophore, led to the identification of lead compound RB394 (Fig. 8) [78]. RB394 is an equipotent PPARδ-selective full agonist and sEH inhibitor with a favorable pharmacokinetic and pharmacodynamic profile. Extensive in vivo profiling of RB394 in spontaneously hypertensive obese rats (SHROB), ZSF-1 (ZSF1-LeprfaLeprcp/Crl) obese rats, and unilateral ureteral obstruction rats (UUO) led to the validation that a simultaneous sEH inhibition and PPARγ activation are highly beneficial for metabolic syndrome. RB394 simultaneously and potently reduced blood pressure, blood glucose level, dyslipidemia and hypercholesteremia, as well as liver and kidney fibrosis in preventive and curative paradigms dosed at 10 mg/kg/day [79].

Schirle et al. took advantage of an anti-inflammatory drug to define further multitarget drugs by selecting an anti-asthmatic CysLT1 receptor antagonist zafirlukast, which also possessed moderate modulating activities against PPARγ and sEH [80]. Minor modifications in the chemical structure of zafirlukast to improve its potential anti-inflammatory action led a potent modulator of PPARγ, sEH, and CysLT1R. This resulted in improved beneficial off-target activities (8.1-fold against PPARγ and 46.5-fold against sEH, respectively) and superior anti-inflammatory properties compared to the parent compound zafirlukast in the zymosan-induced paw edema model (Fig. 9).

2.2.2. Dual inhibitors of sEH and FXR

Bile acids are physiological activators of the farnesoid X receptor (FXR), a ligand-activated nuclear receptor which regulates bile acid, lipid, and glucose homeostasis [81]. FXR agonists are currently under clinical investigation for treatment of nonalcoholic fatty liver disease (NAFDL) and nonalcoholic steatohepatitis (NASH) [82,83]. Genetic deletion or pharmacological inhibition of sEH has been shown to promote anti-inflammatory effects in murine models of high-fat (HF)-diet-induced fatty liver [84,85]. Thus, simultaneous modulation of FXR and sEH might have an additive or synergistic effect in the context of NAFDL and NASH. Schmidt et al. rationally designed a dual sEH/FXR modulator by combining previously published selective partial FXR agonists [86] and sEH inhibitors [87]. Subsequent optimization and a bioisosteric replacement strategy yielded a highly potent, orally available, and efficacious dual sEH/FXR modulator (Fig. 10) [88].

2.2.3. Dual inhibitors of sEH and FAAH

A significant percentage of NSAIDs and other anti-inflammatory drugs, both over-the-counter and prescription, target the modulation of lipids within the ARA cascade. However, there are lipids not related to...
Sorafenib is the pan-kinase inhibitor inhibiting several kinases in addition to c-RAF, the anticancer target [98]. Importantly, sorafenib has been identified as having significant antitumor activity in lung, breast, and ovarian cancers in athymic mice, validating it as an anticancer agent. RAF (originally known as Raf1) was discovered in 1985 [97]. In the early 1990s, Bayer and Onyx cooperated to screen a combinatorial library of about 200,000 compounds against c-RAF to develop a drug targeting the RAS-RAF-MEK-ERK pathway. c-RAF was selected based on the finding that disrupting the RAF1 gene inhibited the tumor growth in lung, breast, and ovarian cancers in athymic mice, validating it as an anticancer target [98]. Importantly, sorafenib has been identified as a pan-kinase inhibitor inhibiting several kinases in addition to c-RAF. Sorafenib is the first FDA-approved drug developed from the screening of combinatorial libraries, which also validates combinatorial chemistry as a valuable tool for drug development. Pan-kinase inhibition helps to treat cancers due to the complex nature of the diseases. However, untargeted (and even on-target) kinase inhibition also causes unwanted adverse effects [99,100]. BRAF is a human gene that encodes for the b-RAF kinase and its mutations, especially V600E, have been targets of several cancer therapies [101]. However, in some cases, b-RAF inhibitors can induce tumor growth [102]. It has been demonstrated that inhibition of b-RAF in RAS mutant cancer cells leads to MEK hyperactivation through c-RAF (Fig. 12) [103]. In addition, it has been known that c-RAF, not b-RAF, is a major player in pancreatic cancer. Furthermore, pancreatic cancer is developed from pancreatic intraepithelial neoplasia (PanIN) which provides strong support for the concepts of polypharmacology [99,100]. Polypharmacology has emerged as a new paradigm in drug discovery over the last two decades. Several approved drugs have been identified retrospectively as having beneficial polypharmacological profiles which provides strong support for the concepts of polypharmacology and multitarget drug design. The next challenge will be

### 3. Summary and perspectives

Polypharmacology has emerged as a new paradigm in drug discovery over the last two decades. Several approved drugs have been identified retrospectively as having beneficial polypharmacological profiles which provides strong support for the concepts of polypharmacology and multitarget drug design. The next challenge will be
to rationally design compounds with desired polypharmacological profiles and transform them into drug candidates. Molecules with optimal multitarget activities have the potential of improving the efficacy and safety of drugs. Targeting sEH as a single target with a single compound has demonstrated great potential as an efficacious and safe strategy for several indications. In fact, sEH inhibitors as single target agents have previously been evaluated in human clinical trials and continue to be pursued for various diseases. Results from several human phase 1 clinical trials [112,113] have demonstrated their safety in humans, which underscores benefit of sEH inhibition. The outcomes from the later phases of human clinical trials will confirm sEH as a valid single target to treat such diseases. By combining the benefits of inhibiting sEH with other targets (Table 1 and Fig. 13), multitarget compounds are safer and, as demonstrated, more efficacious than monotherapy.

Conflict of interest

B.D.H., K.M.W. and S.H.H are inventors of University of California patents on the synthesis and use of sEH/COX-2, sEH/FAAH and sEH/PDE dual inhibitors. The other authors declare that they have no competing of interests.

Table 1

<table>
<thead>
<tr>
<th>Target</th>
<th>Agent</th>
<th>Disease</th>
<th>species</th>
<th>Major outcomes</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>sEH/COX-2</td>
<td>PTUPB</td>
<td>Inflammatory</td>
<td>Rat</td>
<td>Oral PTUPB reduced intraplantar LPS pain in von Frey assay</td>
<td>Hwang et al. [44]</td>
</tr>
<tr>
<td>(Section 2.1.2)</td>
<td></td>
<td>Pain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kidney Disease</td>
<td>Rat</td>
<td>Dual COX-2/sEH inhibitor reduced renal damage and inflammation in ZDF Rats</td>
<td>Hye Khan et al. [45]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cancer</td>
<td>Mouse</td>
<td>Dual Inhibitor PTUPB inhibits Primary Tumor Growth and Metastasis.</td>
<td>Zhang et al. [46]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cancer</td>
<td>Mouse</td>
<td>PTUPB suppresses glioblastoma growth in vitro and in vivo</td>
<td>Li et al. [47]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Parkinson’s disease</td>
<td>Mouse</td>
<td>PTUPB decreased fibrotic markers in liver injury</td>
<td>Harris et al. [49]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Lakkappa et al. [51]</td>
</tr>
<tr>
<td>sEH/FLAP</td>
<td>diflapol</td>
<td>Peritonitis</td>
<td>Mouse</td>
<td>Diflapol blocked leukotriene formation and suppressed neutrophil infiltration</td>
<td>Garscha et al. [53]</td>
</tr>
<tr>
<td>(Section 2.1.3)</td>
<td></td>
<td></td>
<td></td>
<td>Significant inhibition of the edema</td>
<td>Nandha et al. [55]</td>
</tr>
<tr>
<td>sEH/5-LOX</td>
<td>KM55</td>
<td>Edema</td>
<td>LPS</td>
<td>Significantly inhibited the LPS-induced adhesion of leukocytes to endothelial cells</td>
<td>Meier et al. [56]</td>
</tr>
<tr>
<td>(Section 2.1.4)</td>
<td></td>
<td></td>
<td>THP-1, HUVEC cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sEH/PPAR</td>
<td>RB394</td>
<td>Inflammatory</td>
<td>ZSF1 Rat</td>
<td>Reduced blood pressure, blood glucose level, dyslipidemia and hypercholesteremia, as well as liver and kidney fibrosis</td>
<td>Hye Khan et al. [79]</td>
</tr>
<tr>
<td>(Section 2.2.1)</td>
<td></td>
<td>Edema</td>
<td></td>
<td>Superior anti-inflammatory properties in the zymosan-induced paw edema model</td>
<td>Schierle et al. [80]</td>
</tr>
<tr>
<td>sEH/FXR</td>
<td>FXR/sEH dual modulator</td>
<td>Inflammation</td>
<td>HEPG2, HuT-78 cells</td>
<td>Robustly repressed NF-κB in hepatocarcinoma cells and reduced the Pam3CSK4 stimulated release of TNFα from the T-cell line HuT-78</td>
<td>Schmidt et al. [88]</td>
</tr>
<tr>
<td>(Section 2.2.2)</td>
<td></td>
<td></td>
<td></td>
<td>A hit compound, t-TUCB, has been optimized through SAR study. The optimized compounds showed improved cross-species potencies against both FAAH and sEH.</td>
<td>Kodani et al. (2018)</td>
</tr>
<tr>
<td>sEH/FAAH</td>
<td>FAAH/sEH dual inhibitor</td>
<td>Inflammatory</td>
<td>Mouse, PK03 cells</td>
<td>Inhibition of murine pancreatic carcinoma growth in vitro and in vivo by t-CUPM</td>
<td>Liao et al. (2016)</td>
</tr>
<tr>
<td>(Section 2.2.4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fig. 13. Signaling pathways of fatty acids and modes of action of multitarget agents.
Acknowledgments

We would like to thank Dr. Christophe Morisseau for his help during the manuscript preparation. This work was supported by Deutsche Forschungsgemeinschaft (DFG; Sachbeihilfe PR1405/2-2; SFB 1039 Teilprojekt A07; Heisenberg-Professor PR1405/4-1) and by research funding programe Landes-Offensive zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz (LOEWE) of the State of Hessen, Research Center for Translational Medicine and Pharmacology TOMP (to E.P.), by the Else-Krönner-Fresenius Foundation graduate college for Translational Research Innovation-Pharma (TRIP) (to K.H.), by R01 NCI/CA172431 (to B.D.H.); by NIEHS/R01 ES002710 (to B.D.H.); and by NIDDK R01 DK103616 (to B.D.H.).

References

[17] E. Ricciotti, G.A. FitzGerald, Prostaglandins and in

K. Hiesinger et al.

Prostaglandins and Other Lipid Mediators 140 (2019) 31–39